|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
|
EA006227B1
(ru)
|
1999-12-10 |
2005-10-27 |
Пфайзер Продактс Инк. |
СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
US7071189B2
(en)
|
2001-04-27 |
2006-07-04 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active ingredient
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
GB0212049D0
(en)
|
2002-05-24 |
2002-07-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
WO2004019973A1
(en)
|
2002-08-14 |
2004-03-11 |
Atugen Ag |
Use of protein kinase n beta
|
|
JP2006523237A
(ja)
|
2003-04-03 |
2006-10-12 |
セマフォア ファーマシューティカルズ， インコーポレイテッド |
Ｐｉ−３キナーゼインヒビタープロドラッグ
|
|
US7902192B2
(en)
*
|
2003-05-15 |
2011-03-08 |
Arqule, Inc. |
Inhibitors of P38 and methods of using the same
|
|
US7425553B2
(en)
|
2003-05-30 |
2008-09-16 |
Gemin X Pharmaceuticals Canada Inc. |
Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
|
|
CA2531069A1
(en)
|
2003-07-03 |
2005-01-27 |
The Trustees Of The University Of Pennsylvania |
Inhibition of syk kinase expression
|
|
ES2372694T3
(es)
|
2003-10-15 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
|
|
AR049769A1
(es)
*
|
2004-01-22 |
2006-09-06 |
Novartis Ag |
Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
|
|
EP1761540B1
(en)
|
2004-05-13 |
2016-09-28 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
ES2354824T3
(es)
*
|
2004-11-04 |
2011-03-18 |
Vertex Pharmaceuticals, Inc. |
Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
|
|
WO2006070943A1
(ja)
*
|
2004-12-28 |
2006-07-06 |
Takeda Pharmaceutical Company Limited |
縮合イミダゾール化合物およびその用途
|
|
JP4801096B2
(ja)
|
2005-01-19 |
2011-10-26 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
EP2757099B1
(en)
|
2005-05-12 |
2017-08-23 |
AbbVie Bahamas Limited |
Apoptosis promoters
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
JP2009502734A
(ja)
*
|
2005-07-29 |
2009-01-29 |
アステラス製薬株式会社 |
Ｌｃｋ阻害剤としての縮合複素環
|
|
AU2006302179C1
(en)
|
2005-10-07 |
2013-06-20 |
Exelixis, Inc. |
N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
|
US7528143B2
(en)
|
2005-11-01 |
2009-05-05 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
CN103214484B
(zh)
|
2005-12-13 |
2016-07-06 |
因塞特控股公司 |
作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
RU2439074C2
(ru)
|
2006-04-26 |
2012-01-10 |
Ф. Хоффманн-Ля Рош Аг |
ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
|
|
AU2007292924A1
(en)
*
|
2006-09-07 |
2008-03-13 |
Biogen Idec Ma Inc. |
IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
|
|
PL2526933T3
(pl)
|
2006-09-22 |
2015-08-31 |
Pharmacyclics Llc |
Inhibitory kinazy tyrozynowej Brutona
|
|
MX2009002995A
(es)
*
|
2006-09-28 |
2009-04-01 |
Novartis Ag |
Derivados de pirazolo-[1,5-a]-pirimidina y su uso terapeutico.
|
|
KR20090075714A
(ko)
*
|
2006-10-30 |
2009-07-08 |
노파르티스 아게 |
소염제로서의 헤테로시클릭 화합물
|
|
EP2114941B1
(en)
*
|
2006-12-22 |
2015-03-25 |
Astex Therapeutics Limited |
Bicyclic heterocyclic compounds as fgfr inhibitors
|
|
JP5442449B2
(ja)
|
2006-12-22 |
2014-03-12 |
アステックス、セラピューティックス、リミテッド |
新規化合物
|
|
US8486941B2
(en)
|
2007-03-12 |
2013-07-16 |
Ym Biosciences Australia Pty Ltd |
Phenyl amino pyrimidine compounds and uses thereof
|
|
US8394794B2
(en)
|
2007-03-23 |
2013-03-12 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PE20090215A1
(es)
*
|
2007-05-09 |
2009-03-30 |
Novartis Ag |
Compuestos derivados de imidazopiridazinas como inhibidores de cinasa
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
CN101801413A
(zh)
|
2007-07-12 |
2010-08-11 |
托勒克斯股份有限公司 |
采用gitr结合分子的联合疗法
|
|
PE20090506A1
(es)
*
|
2007-07-26 |
2009-05-28 |
Novartis Ag |
DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
CN101932325B
(zh)
|
2007-11-30 |
2014-05-28 |
新联基因公司 |
Ido抑制剂
|
|
TWI444382B
(zh)
|
2008-03-11 |
2014-07-11 |
Incyte Corp |
作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物
|
|
EP2300469B1
(en)
*
|
2008-05-13 |
2015-06-24 |
Novartis AG |
Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
|
|
US20110176972A1
(en)
|
2008-05-29 |
2011-07-21 |
Saint-Gobain Centre De Recherches et D'Etudes Eur |
Cellular structure containing aluminium titanate
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
CA2755285C
(en)
|
2009-03-20 |
2014-02-11 |
Yunxin Y. Bo |
Inhibitors of pi3 kinase
|
|
PT3023438T
(pt)
|
2009-09-03 |
2020-05-08 |
Merck Sharp & Dohme |
Anticorpos anti-gitr
|
|
US8722720B2
(en)
|
2009-10-28 |
2014-05-13 |
Newlink Genetics Corporation |
Imidazole derivatives as IDO inhibitors
|
|
CA2778949C
(en)
*
|
2009-10-30 |
2018-02-27 |
Janssen Pharmaceutica Nv |
Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
|
|
EP2949670B1
(en)
|
2009-12-10 |
2019-02-27 |
F. Hoffmann-La Roche AG |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
PH12018501083A1
(en)
|
2010-03-04 |
2019-02-18 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
|
|
SMT201900074T1
(it)
|
2010-05-04 |
2019-02-28 |
Five Prime Therapeutics Inc |
Anticorpi che legano csf1r
|
|
SG10201912092VA
(en)
|
2010-09-09 |
2020-02-27 |
Pfizer |
4-1bb binding molecules
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US8673905B2
(en)
*
|
2011-03-17 |
2014-03-18 |
Hoffmann-La Roche Inc. |
Imidazo pyrazines
|
|
NO2694640T3
(OSRAM)
|
2011-04-15 |
2018-03-17 |
|
|
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
|
EP2791174B1
(en)
|
2011-12-15 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
|
RU2548363C2
(ru)
*
|
2012-01-25 |
2015-04-20 |
Общество с ограниченной ответственностью "Асинэкс Медхим." |
СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Haspin киназы
|
|
CN104093740B
(zh)
|
2012-02-06 |
2018-01-09 |
弗·哈夫曼-拉罗切有限公司 |
使用csf1r抑制剂的组合物和方法
|
|
CN104114558B
(zh)
*
|
2012-02-21 |
2016-10-26 |
默克专利股份公司 |
呋喃并吡啶衍生物
|
|
ES2674451T3
(es)
*
|
2012-02-21 |
2018-06-29 |
Merck Patent Gmbh |
2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
|
|
JP6049768B2
(ja)
*
|
2012-03-07 |
2016-12-21 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
トリアゾロピラジン誘導体
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CN104684582A
(zh)
|
2012-08-31 |
2015-06-03 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
US9617266B2
(en)
*
|
2013-03-05 |
2017-04-11 |
Merck Patent Gmbh |
Imidazopyrimidine derivatives
|
|
WO2014200882A1
(en)
*
|
2013-06-11 |
2014-12-18 |
Janssen Pharmaceutica Nv |
PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES
|
|
CA2965741C
(en)
|
2014-11-03 |
2022-05-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
EP3307728A4
(en)
*
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
|
|
EP3565817B1
(en)
*
|
2017-01-06 |
2023-06-07 |
The Johns Hopkins University |
Small molecule inhibitors of neutral sphingomyelinase 2 (nsmase2) for the treatment of neurodegenerative diseases
|
|
EP4616913A3
(en)
|
2018-01-29 |
2025-12-10 |
Merck Patent GmbH |
Gcn2 inhibitors and uses thereof
|
|
JP7377207B2
(ja)
|
2018-01-29 |
2023-11-09 |
メルク パテント ゲーエムベーハー |
Ｇｃｎ２阻害剤およびその使用
|